EcoDrugPlus

Melatonin Receptor 1a

Ensembl ID : ENSOKIG00005010058
Gene Symbol: MTNR1A
1 Cross references
136 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSOKIG00005012543
Gene Symbol: MTNR1A
3 Cross references
180 Possible Orthologues:

Melatonin Receptor Type 1a-A

Ensembl ID : ENSOKIG00005015078
Gene Symbol: LOC109894161
3 Cross references
179 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSOKIG00005038396
Gene Symbol: MME
1 Cross references
228 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSOKIG00005017689
Gene Symbol: MME
3 Cross references
227 Possible Orthologues:

Membrane Primary Amine Oxidase-Like

Ensembl ID : ENSOKIG00005005090
Gene Symbol: LOC109898547
3 Cross references
408 Possible Orthologues:

Metabotropic Glutamate Receptor 2

Ensembl ID : ENSOKIG00005036240
Gene Symbol: LOC109900890
3 Cross references
200 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSOKIG00005005239
Gene Symbol: LOC109891612
3 Cross references
200 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSOKIG00005010885
Gene Symbol: LOC109866954
3 Cross references
208 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSOKIG00005022568
Gene Symbol: LOC109888853
3 Cross references
208 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSOKIG00005022135
Gene Symbol: METAP2
3 Cross references
215 Possible Orthologues:

Methionyl Aminopeptidase 2b

Ensembl ID : ENSOKIG00005044856
Gene Symbol: METAP2B
1 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).